8:00 am Check-In & Coffee
8:55 am Chair’s Opening Remarks
Assessing Lymphodepletion to Balance Safety, Access & Clinical Impact
9:00 am Panel Discussion: Re-Evaluating Lymphodepletion to Improve Patient Access & Limit Therapeutic Side Effects
Synopsis
- Consider the need for lymphodepletion on cell therapy to identify opportunities to remove preconditioning from therapies
- Identify characteristics of therapies that avoid lymphodepletion to pinpoint opportunities to broaden their benefits to more therapies
- Examine the impact of lymphodepletion on patient recruitment and accessibility
10:00 am Keynote Presentation: Clinical & Mechanistic Perspective on Bringing Cell Therapies to Autoimmune Disease
Synopsis
- Introducing RNA engineering for cell therapy
- Demonstrating deep and durable responses in patients receiving Descartes-08 without lymphodepletion or inpatient administration
- Insight into mechanisms behind Cartesian Therapeutics’ lead asset, Descartes-08
10:30 am Morning Break & Networking
Preclinical & Translational
Exploring Innovations & Translational Challenges to Define the Future of Autologous & Allogeneic Cell Therapies
11:30 am Panel Discussion: Evaluating the Future of Autologous & Allogeneic Therapies
Synopsis
- Identify the optimal approach to maximize therapeutic efficacy
- Consider patient safety by addressing challenges related to rejection and adverse immune responses in both autologous and allogeneic therapies
- Evaluate if autologous or allogeneic therapies are best for future autoimmune therapy personalization
12:15 pm Overcoming Translational Roadblocks to Accelerate Allogeneic Therapies to Clinic
Synopsis
- Identify current roadblocks in the progression of allogeneic therapies to clinic
- Share actionable strategies to overcome translational and regulatory hurdles
- Highlight Atara Biotherapeutics’ ATA3219 targeting lupus to inform the next steps toward market readiness
12:45 pm Harnessing Insights from GentiBio’s Hypo-Immune Allogeneic Cell Therapy Platform to Advance Allogeneic Cell Therapies
Synopsis
- Explore GNTI-122 autologous Type 1 Diabetes therapy
- Discuss GentiBio’s GNTI-350 hypo-immune allogeneic therapy to uncover key data guiding next-generation autoimmune treatment
- Evaluate the unique characteristics of hypo-immune allogeneic cell therapies over traditional allogeneic approaches
- Apply translational insights to accelerate the progression of allogeneic therapies for autoimmune indications
Clinical
Assessing Strategies to Refine Patient Recruitment, Outcomes & Trial Access
11:30 am Roundtable Discussion: Analyzing Emerging Biomarker Targets to Evaluate Treatment Efficacy & Advance Safety & Patient Access Through Personalized Medicines
Synopsis
- Evaluate CD-19 as a reliable target to track B-cell depletion and monitor treatment response
- Leverage CD-19 tracking to enhance individualized diagnostic and therapeutic strategies in autoimmune diseases
- Explore the development of novel autoimmune-specific biomarkers to enable personalized medicine approaches, inspired by successes in oncology
12:15 pm Evaluating the Impact of Cell Therapy on Patient Safety to Enhance Long-Term Outcomes in B-Cell-Targeted Autoimmune Therapies
Synopsis
- Evaluate clinical safety and monitoring side effects associated with CAR-T therapies
- Investigate prevention of cytokine released syndrome (CRS) and (ICANS) associated with CAR-T and T-cell engagers
- Introducing a small molecule oral immune modulator called CTO-1,681, to effectively enhance safety outcomes and expand patient access
12:45 pm Overcoming Patient Recruitment Barriers to Effectively Manage Clinical Trials & Ensure Reliable Time Efficient Outcomes
Synopsis
- Manage recruitment timelines across multiple centers to maintain trial momentum
- Evaluate clinical logistics and Artiva Biotherapeutics’ patients’ clinical journeys
- Highlight best practices to enhance patient experience and recruitment processes
1:15 pm Lunch & Networking Break
Exploring Target & Modality Innovations to Secure the Future of Autoimmune Cell Therapies
2:15 pm Aligning Biotech Innovation with Investor Priorities to Accelerate Funding & Growth
Synopsis
- Identify key indications, targets, and modalities that drive investor enthusiasm to focus cell therapy innovation
- Clarify what investors prioritize when evaluating biotech opportunities to improve funding success
- Outline strategies for biotech companies to align with investor expectations and secure necessary funding
2:45 pm Session Reserved for Kyverna Therapeutics
3:15 pm Driving Innovation Through Treg Data & Antigen Targeting to Unlock Treg Therapeutic Potential
Synopsis
- Utilize polyclonal Treg data to guide therapeutic direction and inform next-generation cell therapy design
- Highlight PolTREG and Immuthera’s latest Type 1 Diabetes findings to demonstrate clinical progress and therapeutic potential
- Advance disease-specific Treg therapies by leveraging antigen-driven precision for durable immune modulation